Chemical Namegilteritinib
Dosage FormTablet (oral; 40 mg)
Drug ClassKinase inhibitors
CompanyAstellas Pharma
Approval Year2018


  • Indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test
Last updated on 4/20/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xospata (Gilteritinib) Prescribing Information. 2018Astellas Pharma US, Inc, Northbrook, IL